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1. Introduction 
The inhibition of lactate dehydrogenase (L-lactate: 
NAD oxidoreductase, EC 1,l ,1,27) by high concentra- 
tions of the su.&rate, pyruvate, has been attributed 
to the formation of an abortive ternary complex of the 
enzyme, NAD and pyruvate [l-5] . High concentra- 
tions of pyruvate, greater than 0.5 mM, are required 
to observe the inhibition and demonstrate the forma- 
tion of a ternary complex. The effects could be due to 
a contaminant or a form of the substrate present in 
only trace amounts. We have prepared samples of 
pyruvate which give no excess substrate inhibition 
and have obtained suggestive vidence for the chemi- 
cal nature of the inhibitor present in the specimens of 
pyruvate normally used for investigations on lactate 
dehydrogenase. 
2. Materials and methods 
Sodium pyruvate (Calbiochem, Grade A) was 
chromatographed by the method of Von Korff [6] 
and the eluent produced by a linear gradient of HCl 
monitored at 260 and 330 w using a Gilford model 
2000 recording spectrophotometer. NAD, NADH, 
APAD (3-acetylpyridine adenine dinucleotide) were 
obtained from The Boehringer Corporation (London). 
Imidazole was obtained from British Drug Houses 
Ltd. and was recrystallized twice. All other chemicals 
were AnalaR grade or equivalent. The enzyme was 
isolated from pig heart muscle [7] and stored as a 
suspension in 70% ammonium sulphate. The sus- 
pension was diluted with phosphate buffer, treated 
North-Holland Publishing Company - Amsterdam 
with activated charcoal (Fison Ltd.) to remove nucleo- 
tides [8] and dialysed against the buffer used for assay. 
The enzyme was assayed at pH 6.90 using NADH 
(100 PM) in either of two buffer systems: Phosphate 
(0.2 M) or imidazole (0.2 M) HCl containing 0.3 M 
sodium chloride. Pyruvate in acid solution was 
pipetted into the cuvette containing buffer and al- 
lowed to equilibrate for two min. NADH and enzyme 
were then added to start the reaction. The change in 
pH produced by the acid was always less than 0.06 of 
a unit. The reaction was followed at 340 ml.c using&a 
Cary 14 recording spectrophotometer and the initial 
velocity measured. Difference spectra were measured 
in split compartment cells,.using the same instrument. 
3. Results and discussion 
The elution profile of pyruvate is shown in fig. 1. 
The material of peak 1 is not pyruvic acid since it 
fails to oxidise NADH in the presence of lactate de- 
hydrogenase. It has an absorption maximum at 260 
w, unlike pyruvate which has two peaks at 210 and 
330 w. The nature of this material, which does not 
inhibit the enzyme, is not known. On standing in SO~U- 
tion for a few days at pH 4.0 it produces pyruvate as 
shown by enzyme assay and absorption spectrum. ‘, 
Peak 2 reacts as pyruvate in all tests and is considered 
to be highly purified material. 
The initial velocity of the oxidation of NADH 
catalysed by lactate dehydrogenase is the same at high 
(10 mM) and low (0.25 mM) substrate if this purified 
pyruvate is used and the assay is carried out in imida- 
zole buffer. If unpurified pyruvate is used the ratio of 
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Fig. 1. Purification of pyruvate. 0.1 gm Sodium pyruvate was loaded on a column 15 X 1 cm. Gradient elution was carried out 
using 0.1 N HCl and a 250 ml water reservoir with a flow-rate of 20 mlsihr. 
ELUAT E VOLUME (mls) 
initial rates at high and low substrate concentrations 
is 0.8 in the same buffer and even lower, 0.4, in 
phosphate or tris buffers [9,10] . The material 
which causes inhibition by high concentrations of 
pyruvate can clearly be removed from the substrate 
and the inhibition is not, therefore, caused by excess 
substrate per se. 
If the purified pyruvate is neutralised in imidazole 
buffer, allowed to stand for five min and then used 
for assay, the ratio of rates obtained for high and low 
substrate concentrations is 0.8, the same as unpurified 
pyruvate. The inhibitor is thus formed rapidly at 
neutral pH valves. Indeed it is formed so rapidly in 
the presence of phosphate that purified and unpuri- 
fied pyruvate behave identically in assays with the 
enzyme if phosphate buffers are used. Pyruvate can 
be quantitatively assayed with lactate dehydrogenase 
in the presence of excess NADH. By this means we 
have shown that purified pyruvate is stable at pH 1 .O 
for several hr at 0°C. 
When pyruvate is added to a mixture of lactate 
dehydrogenase and NAD the absorption spectrum 
changes and a peak at 325 m~.1 appears [l--S]. The 
rate of appearance of this peak can be measured in a 
Cary Model 14 spectrophotometer. The kinetic data 
reported in table 1 show that the rate of formation of 
this peak in imidazole buffer is reduced if purified 
pyruvate is used. 
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Table 1 
Rate of appearance of 325 rnw peak. 
Phosphate Buffer lmidazole Buffer 
(units: increase in absorbance 
per min) 
Purified pyruvate 0.027 0.016 
Unpurified pyruvate 0.03 0.023 
Pyruvate (10 mM final concentration) was added directly to 
the enzyme (14.4 nN) in buffer in the cuvette and allowed 
two min to equilibrate. NAD (0.1 mM, final concentration) 
was added to start the reaction. pH 6.90, 25O. 
The evidence we have presented established that 
excess pyruvate inhibition is due to a substance 
which can be removed from pyruvate solutions and 
which is in rapid equilibrium with pyruvate at neutral 
or alkaline pH valves. The equilibration of the inhibitor 
with pyruvate seems to be subject to catalysis by buffer 
components, especially phosphates. It has been shown 
[ 1 l- 131 by N.M.R. and infrared spectroscopy that the 
hydrate (2,2-dihydroxypropionic acid) is present in 
acid solutions of pyruvate. This compound cannot be 
the inhibitor as it cannot be observed at neutral pH 
values. The enol form of pyruvate would seem to be 
the only remaining possibility. Further data support- 
ing this idea is shown in figs. 2 and 3. Clyoxalate, 
which cannot enolise, shows neither substrate inhibi- 
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Fig. 2. Difference spectrum on combination of sodium Zoxobutyrate with APAD and lactate dehydrogenase. Split compartment 
cells were used and the measurements were in phosphate buffer 0.025 M pH 6.90 at 25O. Contents of compartments: (1) APAD 
(100 PM) + enzyme (14.4 PN); (2) Sodium 2-oxobutyrate (10 mM). 
tion nor ternary complex formation. In contrast, 
Zoxobutyrate, which can enolise, forms a ternary 
complex with the enzyme and APAD with a peak at 
335 ~JJ and shows inhibition at high substrate con- 
centrations. 
In view of the fact that complexes are formed be- 
tween the enol forms of aromatic keto acids and boric 
acid [ 18,191 the effects of boric acid on ternary com- 
plex formation and substrate inhibition have been in- 
vestigated and the results are given in table 2. These 
results, which are preliminary, are consistent with 
the idea that boric acid sequesters the inhibitor and 
thus reduces the rate of ternary complex formation. 
We propose that the abortive ternary complex is 
formed by the addition of carbon-3 of the enol of 
pyruvate to the 4position of the pyridine ring of 
NAD, producing a substituted 1 ,Cdihydronicotin- 
amide adduct. The reaction is analogous to the trans- 
fer of a hydride ion from lactate as illustrated in fig. 
4, which shows only the overall process. Similar enol 
additions to NAD have been shown with acetone [ 171 
and pyruvate [ 14- 161 in chemical model systems. 
Addition of nucleophiles to the 4-position of the nico- 
tinamide ring of NAD is catalysed by the enzyme 
[20,21] and the addition of the enol of pyruvate 
would be particularly favoured as it is a substrate 
analogue. We have shown that semicarbazide reacts 
with NAD in the presence, but not the absence of the 
enzyme, at pH values around 9.0 to give a material 
with an absorption peak at 338 m/.~ The adduct pro- 
duced is a very powerful inhibitor of the enzyme and 
this could explain the different values for the pH op- 
timum of lactate oxidation reported in the literature. 
Winer and Schwert [22] used semicarbazide as a pyru- 
vate trap and obtained a value of 8.8 whereas Sawaki 
and co-workers [23] report a value of 10.0 in the ab- 
sence of semicarbazide. 
As a test of the hypothesis, the pyruvate adducts 
of NAD and APAD were prepared by addition of 
pyruvate to the coenzymes in alkali [ 14-161 and 
examined as enzyme inhibitors. The adduct with 
APAD was found to be a very powerful inhibitor and 
50% inhibition was obtained with this compound at 
0.01 PM concentration. It is of interest that this ex- 
tremely powerful inhibitor can be pictured as an ana- 
logue of the transition state of the hydride transfer 
reaction. The adduct is unstable at pH 6.90 and the 
characteristic 362 nqu peak disappears at this pH 
with a half-life of about six min. In contrast the ad- 
duct with NAD is stable in neutral solution but inhi- 
bits no more powerfully than does NAD. However, in 
this compound the keto group of the pyruvate is 
probably condensed with the amide group of the nico- 
tinamide ring of NAD to give a reduced naphythyri- 
done [ 15- 17,24,25] which would not be a transition 
state analogue. 
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Table 2 
Effects of borate on lactate dehydrogenase. 
June 1969 
Ternary complex formation Substrate inhibition 
(change in absorbance at Rate at 10 mM 
325 mp/min) Rate at 0.25 mM 
No Boric Acid 0.023 0.80 
With Boric Acid bO.006 1.18 
Where indicated boric acid (0.1 M) incubated with pyruvate for two min before addition of enzyme and NAD or NADH. Condi- 
tions for assay as for Methods section and for ternary complex formation as table 1. Imidazole was the buffer. 
[a) Hydride Transfer . 
I-GLYOXALATE VELOCITY/CONCENTRATION PROFILE 
i i 6 8 10 
CONCENTRATION (mM) 
Z-OXOBUTYRATE VELOCITY/CONCENTRATION PROFILE 
___---- -+- 
i ; 8 1 lb 
CONCENTRATION(mM ) 
Fig. 3. Effects of concentration on initial velocity for glyoxy- 
late [l] and Zoxobutyrate [ 21. Substrate incubated with 
NADH (0.1 mM) in buffer pH 6.90, 25%. LDH (3.15 ng/ml) 
added to start the reaction. Phosphate (0.1 M) - solid line. 
Imidazole (0.1 M) containing 0.15 M NaCl - &shed line. 
Ib) En01 Addition 
‘coo- 
l 
c -&?!I&, c i . . CH2 
c-0 H-B 
(g_ y-j........ 
Fig. 4. Comparison of hydride transfer reaction from sub- 
strate with adduct formation from enol pyruvate. 
To summarise it has been demonstrated that pyru- 
vate can be prepared which is free of inhibitor for 
lactate dehydrogenase. All the evidence strongly indi- 
cates that the enol form of pyruvate is responsible for 
excess substrate inhibition. We have suggested a mole- 
cular basis for the inhibition and we have presented 
evidence to show that the suggested adduct is indeed 
a powerful inhibitor. 
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